Senti Bio's Cancer Treatment Gets Major FDA Recognition
Senti Bio receives FDA's RMAT designation for SENTI-202, a breakthrough cell therapy showing promising results in treating relapsed acute myeloid leukemia patients.
/ 907 items
#Healthcare↓
CVS Health Boosts 2025 Outlook, Forecasts Strong 2026 Growth
CVS Health raises 2025 revenue guidance to $400B and projects adjusted earnings of $7.00-$7.20 per share for 2026, signaling turnaround momentum under CEO David Joyner.
JPMorgan Starts Coverage on Vor Bio with Bullish Outlook
JPMorgan initiates coverage of Vor Bio with an Overweight rating and a $43 price target, highlighting strong confidence in telitacicept and major valuation upside.
90% Success: Exicure's Burixafor Helps Myeloma Stem Cell Collection
Exicure shares positive Phase 2 data on burixafor (GPC-100) showing reliable and rapid stem cell mobilization for autologous transplant in multiple myeloma patients, even those with prior challenging therapies.
TERN-701 Shows 64% Response Rate in Hard-to-Treat Leukemia
Terns Pharmaceuticals (TERN) announces encouraging Phase 1 results for TERN-701, showing 64% response rates in relapsed/refractory chronic myeloid leukemia patients with favorable safety profile.
Encouraging Results for Bexobrutideg in Difficult-to-Treat Blood Cancer
Nurix Therapeutics presented positive Phase 1 data for its BTK degrader, bexobrutideg (NX-5948), showing high response rates and favorable safety in heavily pre-treated Waldenström Macroglobulinemia patients.